[go: up one dir, main page]

SI2273985T1 - Kapsula za preprečevanje kardiovaskularnih bolezni - Google Patents

Kapsula za preprečevanje kardiovaskularnih bolezni

Info

Publication number
SI2273985T1
SI2273985T1 SI200931435A SI200931435A SI2273985T1 SI 2273985 T1 SI2273985 T1 SI 2273985T1 SI 200931435 A SI200931435 A SI 200931435A SI 200931435 A SI200931435 A SI 200931435A SI 2273985 T1 SI2273985 T1 SI 2273985T1
Authority
SI
Slovenia
Prior art keywords
capsule
prevention
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
SI200931435A
Other languages
English (en)
Inventor
Marta Guerrero
Anna Orriols
Pablo Martin
Manuel Raga
Original Assignee
Ferrer Internacional, S.A.
CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40010466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2273985(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Internacional, S.A., CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III filed Critical Ferrer Internacional, S.A.
Publication of SI2273985T1 publication Critical patent/SI2273985T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200931435A 2008-03-28 2009-03-25 Kapsula za preprečevanje kardiovaskularnih bolezni SI2273985T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08153615 2008-03-28
PCT/EP2009/053545 WO2009118359A2 (en) 2008-03-28 2009-03-25 Capsule for the prevention of cardiovascular diseases
EP09724677.1A EP2273985B1 (en) 2008-03-28 2009-03-25 Capsule for the prevention of cardiovascular diseases

Publications (1)

Publication Number Publication Date
SI2273985T1 true SI2273985T1 (sl) 2016-06-30

Family

ID=40010466

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931435A SI2273985T1 (sl) 2008-03-28 2009-03-25 Kapsula za preprečevanje kardiovaskularnih bolezni

Country Status (34)

Country Link
US (1) US8753680B2 (sl)
EP (1) EP2273985B1 (sl)
JP (1) JP2011515445A (sl)
KR (1) KR20110007602A (sl)
CN (1) CN101980701A (sl)
AR (1) AR071094A1 (sl)
AU (1) AU2009228832A1 (sl)
BR (1) BRPI0909254A2 (sl)
CA (1) CA2720800C (sl)
CL (1) CL2009000767A1 (sl)
CO (1) CO6311069A2 (sl)
CR (1) CR11736A (sl)
CY (1) CY1117556T1 (sl)
DK (1) DK2273985T3 (sl)
EC (1) ECSP10010562A (sl)
ES (1) ES2569553T3 (sl)
GT (1) GT201000275A (sl)
HN (1) HN2010001979A (sl)
HR (1) HRP20160416T1 (sl)
HU (1) HUE028919T2 (sl)
IL (1) IL208455A0 (sl)
IS (1) IS8932A (sl)
MA (1) MA32347B1 (sl)
MX (1) MX2010010479A (sl)
NI (1) NI201000159A (sl)
NZ (1) NZ588239A (sl)
PL (1) PL2273985T3 (sl)
RU (1) RU2477123C2 (sl)
SI (1) SI2273985T1 (sl)
SV (1) SV2010003684A (sl)
TW (1) TW200944251A (sl)
UA (1) UA99758C2 (sl)
UY (1) UY31741A (sl)
WO (1) WO2009118359A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN103006612B (zh) * 2012-12-28 2014-07-02 石雷 一种赖诺普利迟释缓释片剂及其制备方法
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2016139982A1 (ja) * 2015-03-05 2016-09-09 日本電気株式会社 無線設備の故障判定方法及び移動体無線システム
BE1023011B1 (nl) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylzuur tablet met onmiddellijke afgifte
ES2695503B2 (es) 2017-06-30 2020-05-08 Pharmalink S L Formulaciones encapsuladas
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
HUE066396T2 (hu) 2022-06-30 2024-08-28 Ferrer Int Orális kapszulák, amelyek atorvasztatin tablettákat tartalmaznak, amelyek megfelelõ oldódási profilt és biológiai hozzáférhetõséget mutatnak
CN115671077B (zh) * 2022-11-18 2024-09-17 乐普药业股份有限公司 一种预防心脑血管疾病的复方微丸胶囊及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
JP2544052B2 (ja) * 1991-12-18 1996-10-16 日本エランコ株式会社 硬質ゼラチンカプセルへの錠剤充填装置
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
PL202884B1 (pl) 2000-02-10 2009-07-31 Bpsi Holdings Nietoksyczna, jadalna, powłokotwórcza kompozycja proszkowa zabezpieczająca przed działaniem soku żołądkowego, sposób sporządzania wodnego układu dyspersyjnego oraz sposób powlekania substratów
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2004080488A2 (de) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
US20050026992A1 (en) 2003-07-28 2005-02-03 Sasmal Badal Kumar Treatment and prevention of cardiovascular events
JP4680061B2 (ja) * 2003-08-20 2011-05-11 塩野義製薬株式会社 新規コーティング組成物
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US20120015032A1 (en) 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same

Also Published As

Publication number Publication date
UA99758C2 (ru) 2012-09-25
EP2273985A2 (en) 2011-01-19
US20110086094A1 (en) 2011-04-14
CN101980701A (zh) 2011-02-23
US8753680B2 (en) 2014-06-17
WO2009118359A3 (en) 2010-05-06
UY31741A (es) 2009-12-14
IL208455A0 (en) 2010-12-30
AU2009228832A1 (en) 2009-10-01
CA2720800C (en) 2013-07-30
CR11736A (es) 2011-05-11
WO2009118359A2 (en) 2009-10-01
IS8932A (is) 2010-10-05
GT201000275A (es) 2015-09-30
NZ588239A (en) 2011-09-30
ES2569553T3 (es) 2016-05-11
TW200944251A (en) 2009-11-01
DK2273985T3 (en) 2016-04-25
KR20110007602A (ko) 2011-01-24
RU2010144131A (ru) 2012-05-10
EP2273985B1 (en) 2016-02-17
HRP20160416T1 (hr) 2016-06-17
SV2010003684A (es) 2011-03-31
HN2010001979A (es) 2013-07-01
NI201000159A (es) 2011-08-02
CA2720800A1 (en) 2009-10-01
AR071094A1 (es) 2010-05-26
MX2010010479A (es) 2011-02-22
CO6311069A2 (es) 2011-08-22
RU2477123C2 (ru) 2013-03-10
HUE028919T2 (en) 2017-01-30
CY1117556T1 (el) 2017-04-26
PL2273985T3 (pl) 2016-08-31
JP2011515445A (ja) 2011-05-19
CL2009000767A1 (es) 2009-08-14
ECSP10010562A (es) 2011-04-29
MA32347B1 (fr) 2011-06-01
BRPI0909254A2 (pt) 2017-01-10

Similar Documents

Publication Publication Date Title
IL208455A0 (en) Capsule for the prevention of cardiovascular diseases
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
AP2860A (en) Carbazole compounds and therapeutic uses of the compounds
ZA201004793B (en) Capsule formulation
ZA201008536B (en) Suppression of neuroendocrine diseases
GB0921075D0 (en) Novel combination of the therapeutic agents
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
PT1992575E (pt) Cápsula para produtos de infusão
EG26332A (en) Process for the preparation of benzonoprons
ZA201007362B (en) Conjugates for the treatment of mesothelioma
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
PL2151429T3 (pl) Nowy sposób syntezy agomelatyny
GB2471453B (en) Fragrance capsule
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
PL2285780T3 (pl) Sposoby i związki do wytwarzania normorfinanów
IL211382A0 (en) Process for the preparation of ethanedinitrile
GB0716840D0 (en) Treatment of cardiovascular disease
PL384700A1 (pl) Sposób syntezy 1-propenyloksyalkoholu
PL384973A1 (pl) Sposób otrzymywania erytrytolu
GB0911657D0 (en) Novel compounds and improved treatmemts for cardiac and cardiovascular disease
PH32007000328S1 (en) Capsule chamber
GB0809319D0 (en) The treatment of puritus
PL384594A1 (pl) Sposób otrzymywania polisacharydu nieskrobiowego ze zbóż
PL387383A1 (pl) Sposób otrzymywania fosfolipidów
GB0812613D0 (en) Process for the preparation of 1-deoxyidonojirimycin